Management of Perioperative Myocardial Infarction in Noncardiac Surgical Patients

      Perioperative myocardial infarction (PMI) is a major cause of morbidity and mortality in patients undergoing noncardiac surgery. The incidence of PMI varies depending on the method used for diagnosis and is likely to increase as the population ages. Studies have examined different methods for prevention of myocardial infarction (MI), including the use of perioperative β-blockers, α2-agonists, and statin therapy. However, few studies have focused on the treatment of PMI. Current therapy for acute MI generally involves anticoagulation and antiplatelet therapy, raising the potential for surgical site hemorrhage in this population. This article reviews the possible mechanisms, diagnosis, and treatment options for MI in the surgical setting. We also suggest algorithms for treatment.


      To read this article in full you will need to make a payment
      Subscribe to CHEST
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Badner NH
        • Knill RL
        • Brown JE
        • et al.
        Myocardial infarction after noncardiac surgery.
        Anesthesiology. 1998; 88: 572-578
        • Tarhan S
        • Moffitt EA
        • Taylor WF
        • et al.
        Myocardial infarction after general anesthesia.
        JAMA. 1972; 220: 1451-1454
        • Becker RC
        • Underwood DA
        Myocardial infarction in patients undergoing noncardiac surgery.
        Cleve Clin J Med. 1987; 54: 25-28
        • Ashton MC
        • Petersen JN
        • Wray PN
        • et al.
        The incidence of perioperative myocardial infarction in men undergoing noncardiac surgery.
        Ann Intern Med. 1993; 118: 504-510
        • Eagle KA
        • Rihal CS
        • Mickel MC
        • et al.
        Cardiac risk of noncardiac surgery: influence of coronary disease and type of surgery in 3368 operations.
        Circulation. 1997; 96: 1882-1887
        • Landesberg G
        • Mosseri M
        • Zahger D
        • et al.
        Myocardial infarction following vascular surgery: the role of prolonged, stress-induced, ST-depression-type ischemia.
        J Am Coll Cardiol. 2001; 37: 1839-1845
        • Landesberg G
        • Shatz V
        • Akopnik I
        • et al.
        Association of cardiac troponin, CK-MB, and postoperative myocardial ischemia with long-term survival after major vascular surgery.
        J Am Coll Cardiol. 2003; 42: 1547-1554
        • Landesberg G
        • Mosseri M
        • Shatz V
        • et al.
        Cardiac troponin after major vascular surgery: the role of perioperative ischemia, preoperative thallium scanning, and coronary revascularization.
        J Am Coll Cardiol. 2004; 44: 569-575
        • Landesberg G
        • Luria MH
        • Cotev S
        • et al.
        Importance of long-duration postoperative ST-segment depression in cardiac morbidity after vascular surgery.
        Lancet. 1993; 341: 715-719
        • Mangano DT
        • Hollenberg M
        • Fegert G
        • et al.
        Perioperative myocardial ischemia in patients undergoing noncardiac surgery: I. Incidence and severity during the 4-day perioperative period.
        J Am Coll Cardiol. 1991; 17: 843-850
        • Hertzer NR
        • Beven EG
        • Young JR
        • et al.
        Coronary artery disease in peripheral vascular patients: a classification of 1000 coronary arteriograms and results of surgical management.
        Ann Surg. 1984; 199: 223-233
        • Sprung J
        • Abdelmalak B
        • Gottlieb A
        • et al.
        Analysis of risk factors for myocardial infarction and cardiac mortality after major vascular surgery.
        Anesthesiology. 2000; 93: 129-140
        • Diehl JT
        • Cali RF
        • Hertzer NR
        • et al.
        Complications of abdominal aortic reconstruction: an analysis of perioperative risk factors in 557 patients.
        Ann Surg. 1983; 197: 49-56
        • Barone EJ
        • Bull J
        • Cussatti EH
        • et al.
        Perioperative myocardial infarction in low-risk patients undergoing noncardiac surgery is associated with intraoperative hypotension.
        J Intensive Care Med. 2002; 17: 250-255
        • Eagle KA
        • Berger PB
        • Calkins H
        • et al.
        ACC/AHA guideline update for perioperative cardiovascular evaluation for Noncardiac surgery–executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery).
        J Am Coll Cardiol. 2002; 39: 542-553
        • Kaluza GL
        • Joseph J
        • Lee JR
        • et al.
        Catastrophic outcomes of noncardiac surgery soon after coronary stenting.
        J Am Coll Cardiol. 2000; 35: 1288-1294
        • Wilson SH
        • Fasseas P
        • Orford JL
        • et al.
        Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting.
        J Am Coll Cardiol. 2003; 42: 234-240
        • Breslow MJ
        • Parker SD
        • Frank SM
        • et al.
        Determinants of catecholamine and cortisol responses to lower extremity revascularization. The PIRAT Study Group.
        Anesthesiology. 1993; 79: 1202-1209
        • Sametz W
        • Metzler H
        • Gries M
        • et al.
        Perioperative catecholamine changes in cardiac risk patients.
        Eur J Clin Invest. 1999; 29: 582-587
        • Indolfi C
        • Ross Jr, J
        The role of heart rate in myocardial ischemia and infarction: implications of myocardial perfusion-contraction matching.
        Prog Cardiovasc Dis. 1993; 36: 61-74
        • Ambrose JA
        • Tannenbaum MA
        • Alexopoulos D
        Angiographic progression of coronary artery disease and the development of myocardial infarction.
        J Am Coll Cardiol. 1988; 12: 56-62
        • Brown G
        • Albers JJ
        • Fisher LD
        • et al.
        Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
        N Engl J Med. 1990; 323: 1289-1298
        • Ellis SG
        • Hertzer NR
        • Young JR
        • et al.
        Angiographic correlates of cardiac death and myocardial infarction complicating major nonthoracic vascular surgery.
        Am J Cardiol. 1996; 77: 1126-1128
        • Sautter RD
        • Myers WO
        • Ray 3rd, JF
        • et al.
        Relationship of fibrinolytic system to postoperative thrombotic phenomena.
        Arch Surg. 1973; 107: 292-296
        • Dawood M
        • Gutpa DK
        • Southern J
        • et al.
        Pathology of fatal perioperative myocardial infarction: implications regarding pathophysiology and prevention.
        Int J Cardiol. 1996; 57: 37-44
        • Cohen MC
        • Aretz TH
        Histological analysis of coronary artery lesions in fatal postoperative myocardial infarction.
        Cardiovasc Pathol. 1999; 8: 133-139
        • Lee TH
        Reducing cardiac risk in noncardiac surgery.
        N Engl J Med. 1999; 341: 1838-1840
        • Poldermans D
        • Boersma E
        • Bax JJ
        • et al.
        The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group.
        N Engl J Med. 1999; 341: 1789-1794
        • Mangano DT
        • Layug EL
        • Wallace A
        • et al.
        Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery.
        N Engl J Med. 1996; 335: 1713-1720
        • Zimmerman J
        • Fromm R
        • Meyer D
        • et al.
        Diagnostic marker cooperative study for the diagnosis of myocardial infarction.
        Circulation. 1999; 99: 1671-1677
        • Zimetbaum PJ
        • Josephson ME
        Use of the electrocardiogram in acute myocardial infarction.
        N Engl J Med. 2003; 348: 933-940
        • Martinez EA
        • Kim LJ
        • Faraday N
        • et al.
        Sensitivity of routine intensive care unit surveillance for detecting myocardial ischemia.
        Crit Care Med. 2003; 31: 2302-2308
        • Hossein-Nia M
        • Kallis P
        • Brown PA
        • et al.
        Creatine kinase MB isoforms: sensitive markers of ischemic myocardial damage.
        Clin Chem. 1994; 40: 1265-1271
        • Wu AH
        • Apple FS
        • Gibler WB
        • et al.
        National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases.
        Clin Chem. 1999; 45: 1104-1121
        • Lee TH
        • Thomas EJ
        • Ludwig LE
        • et al.
        Troponin T as a marker for myocardial ischemia in patients undergoing major noncardiac surgery.
        Am J Cardiol. 1996; 77: 1031-1036
        • Adams 3rd, JE
        • Sicard GA
        • Allen BT
        • et al.
        Diagnosis of perioperative myocardial infarction with measurement of cardiac troponin I.
        N Engl J Med. 1994; 330: 670-674
        • Schreiber WE
        Laboratory assessment of myocardial damage.
        Am J Clin Path. 1997; 107: 383-384
        • Horwich TB
        • Patel J
        • Mac Lellan WR
        • et al.
        Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure.
        Circulation. 2003; 108: 833-838
        • Giannitsis E
        • Muller-Bardorff M
        • Kurowski V
        • et al.
        Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism.
        Circulation. 2000; 102: 211-217
        • Ver Elst KM
        • Spapen HD
        • Nguyen DN
        • et al.
        Cardiac troponins T and I are biological markers of left ventricular dysfunction in septic shock.
        Clin Chem. 2000; 46: 650-657
        • Alpert JS
        • Thygesen K
        • Antman E
        • et al.
        Myocardial infarction redefined: a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction.
        J Am Coll Cardiol. 2000; 36: 959-969
        • Lopez-Jimenez F
        • Goldman L
        • Sacks DB
        • et al.
        Prognostic value of cardiac troponin T after noncardiac surgery: 6-month follow-up data.
        J Am Coll Cardiol. 1997; 29: 1241-1245
        • Kim LJ
        • Martinez EA
        • Faraday N
        • et al.
        Cardiac troponin I predicts short-term mortality in vascular surgery patients.
        Circulation. 2002; 106: 2366-2371
        • Bertrand ME
        • Simoons ML
        • Fox KA
        Management of acute coronary syndromes: acute coronary syndromes without persistent ST segment elevation: recommendations of the Task Force of the European Society of Cardiology.
        Eur Heart J. 2000; 21: 1406-1432
        • Antman EM
        • Cohen M
        • Bernink PJ
        • et al.
        The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making.
        JAMA. 2000; 284: 835-842
        • Morrow DA
        • Cannon CP
        • Rifai N
        • et al.
        TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial.
        JAMA. 2001; 286: 2405-2412
        • Silber J
        • Albertsson P
        • Aviles FF
        • et al.
        Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.
        Eur Heart J. 1995; 26: 804-847
        • Boersma E
        • Pieper KS
        • Steyerberg EW
        • et al.
        Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. The PURSUIT Investigators.
        Circulation. 2000; 101: 2557-2567
        • Cannon CP
        Evidence-based risk stratification to target therapies in acute coronary syndromes.
        Circulation. 2002; 106: 1588-1591
        • de Lemos JA
        • Morrow DA
        • Bentley JH
        • et al.
        The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes.
        N Engl J Med. 2001; 345: 1014-1021
        • Sabatine MS
        • Morrow DA
        • de Lemos JA
        • et al.
        Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide.
        Circulation. 2002; 105: 1760-1763
      1. Gruppo Italiano por lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.
        Lancet. 1986; 327: 397-402
      2. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction.
        N Engl J Med. 1993; 329: 673-682
      3. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction.
        N Engl J Med. 1997; 337: 1118-1123
        • Franzosi MG
        • Santoro E
        • De Vita C
        • et al.
        Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction: results of the Gruppo Italiano por lo Studio della Sopravvivenza nell'Infarto-1 study.
        Circulation. 1998; 98: 2659-2665
        • Antman EM
        • Anbe DT
        • Armstrong PW
        • et al.
        ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: executive summary: a report of the ACC/AHA Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines on the Management of Patients With Acute Myocardial Infarction).
        J Am Coll Cardiol. 2004; 44: 671-719
      4. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Harker LA
        • Boissel JP
        • Pilgrim AJ
        • et al.
        Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE.
        Drug Saf. 1999; 21: 325-335
        • Grines CL
        • Browne KF
        • Marco J
        • et al.
        A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction.
        N Engl J Med. 1993; 328: 673-679
        • Berger BP
        • Bellot V
        • Bell MR
        • et al.
        An immediate invasive strategy for the treatment of acute myocardial infarction early after noncardiac surgery.
        Am J Cardiol. 2001; 87: 1100-1102
        • Antman EM
        • Cohen M
        • Radley D
        • et al.
        Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction: TIMI 11B-ESSENCE meta-analysis.
        Circulation. 1999; 100: 1602-1608
      5. The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin.
        Lancet. 1990; 336: 71-75
      6. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction.
        Lancet. 2001; 358: 605-613
      7. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction.
        Lancet. 1994; 343: 1115-1122
      8. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction.
        Lancet. 1995; 345: 669-685
        • Lau J
        • Antman EM
        • Jimenez-Silva J
        • et al.
        Cumulative meta-analysis of therapeutic trials for myocardial infarction.
        N Engl J Med. 1992; 327: 248-254
        • Gottlieb SS
        • Mc Carter RJ
        • Vogel RA
        Effect of β-blockade on mortality among high-risk and low-risk patients after myocardial infarction.
        N Engl J Med. 1998; 339: 489-497
        • Koenig W
        • Lowel H
        • Lewis M
        • et al.
        Long-term survival after myocardial infarction: relationship with thrombolysis and discharge medication; results of the Augsburg Myocardial Infarction Follow-up Study 1985 to 1993.
        Eur Heart J. 1996; 17: 1199-1206
        • Leitch JW
        • Mc Elduff P
        • Dobson A
        • et al.
        Outcome with calcium channel antagonists after myocardial infarction: a community-based study.
        J Am Coll Cardiol. 1998; 31: 111-117
        • Lonn EM
        • Yusuf S
        • Jha P
        • et al.
        Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection.
        Circulation. 1994; 90: 2056-2069
      9. Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1).
        Lancet. 1995; 345: 686-687
      10. ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials.
        Circulation. 1998; 97: 2202-2212
        • Brown NJ
        • Vaughan DE
        Angiotensin-converting enzyme inhibitors.
        Circulation. 1998; 97: 1411-1420
        • Pfeffer MA
        ACE inhibitors in acute myocardial infarction: patient selection and timing.
        Circulation. 1998; 97: 2192-2194
        • Sigurdsson A
        • Swedberg K
        Left ventricular remodelling, neurohormonal activation and early treatment with enalapril (CONSENSUS II) following myocardial infarction.
        Eur Heart J. 1994; 15 (discussion 26–30): 14-19
        • Yusuf S
        • Sleight P
        • Pogue J
        • et al.
        Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators.
        N Engl J Med. 2000; 342: 145-153
        • Schwartz GG
        • Olsson AG
        • Ezekowitz MD
        • et al.
        Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study; a randomized controlled trial.
        JAMA. 2001; 285: 1711-1718
        • Aronow HD
        • Topol EJ
        • Roe MT
        • et al.
        Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.
        Lancet. 2001; 357: 1063-1068
        • Gurbel PA
        • Anderson RD
        • Mac Cord CS
        • et al.
        Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.
        Circulation. 1994; 89: 361-365
        • Kono T
        • Morita H
        • Nishina T
        • et al.
        Aortic counterpulsation may improve late patency of the occluded coronary artery in patients with early failure of thrombolytic therapy.
        J Am Coll Cardiol. 1996; 28: 876-881
        • O'Rourke MF
        • Norris RM
        • Campbell TJ
        • et al.
        Randomized controlled trial of intraaortic balloon counterpulsation in early myocardial infarction with acute heart failure.
        Am J Cardiol. 1981; 47: 815-820
        • Ohman EM
        • Califf RM
        • George BS
        • et al.
        The use of intraaortic balloon pumping as an adjunct to reperfusion therapy in acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) Study Group.
        Am Heart J. 1991; 121: 895-901
        • Kovack PJ
        • Rasak MA
        • Bates ER
        • et al.
        Thrombolysis plus aortic counterpulsation: improved survival in patients who present to community hospitals with cardiogenic shock.
        J Am Coll Cardiol. 1997; 29: 1454-1458
        • Kohchi K
        • Takebayashi S
        • Block PC
        • et al.
        Arterial changes after percutaneous transluminal coronary angioplasty: results at autopsy.
        J Am Coll Cardiol. 1987; 10: 592-599
        • White CJ
        • Ramee SR
        • Collins TJ
        • et al.
        Coronary thrombi increase PTCA risk: angioscopy as a clinical tool.
        Circulation. 1996; 93: 253-258
        • Haude M
        • Höpp HW
        • Rupprecht HJ
        • et al.
        Immediate stent implantation versus conventional techniques for the treatment of abrupt vessel closure or symptomatic dissections after coronary balloon angioplasty.
        Am Heart J. 2000; 140: 820-830
        • Topol EJ
        Coronary-artery stents: gauging, gorging, and gouging.
        N Engl J Med. 1998; 339: 1702-1704
        • Mak KH
        • Belli G
        • Ellis SG
        • et al.
        Subacute stent thrombosis: evolving issues and current concepts.
        J Am Coll Cardiol. 1996; 27: 494-503
        • Madsen JK
        • Grande P
        • Saunamäki K
        • et al.
        Danish multicenter randomized study of invasive versus conservative treatment in patients with inducible ischemia after thrombolysis in acute myocardial infarction (DANAMI).
        Circulation. 1997; 96: 748-755
      11. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment.
        BMJ. 1988; 296: 320-331
        • Freemantle N
        • Urdahl H
        • Eastaugh J
        • et al.
        What is the place of β-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis)interpretation.
        Prog Cardiovasc Dis. 2002; 44: 243-250
        • Aronow HD
        • Topol EJ
        • Roe MT
        • et al.
        Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study.
        Lancet. 2001; 357: 1063-1068
        • Stenestrand U
        • Wallentin L
        Early statin treatment following acute myocardial infarction and 1-year survival.
        JAMA. 2001; 285: 430-436
        • Zaugg M
        • Tagliente T
        • Lucchinetti E
        • et al.
        Beneficial effects from β-adrenergic blockade in elderly patients undergoing noncardiac surgery.
        Anesthesiology. 1999; 91: 1674-1686
        • Auerbach AD
        • Goldman L
        β-Blockers and reduction of cardiac events in noncardiac surgery: scientific review.
        JAMA. 2002; 287: 1435-1444
        • Yang H
        • Raymer K
        • Butler R
        • et al.
        Metoprolol after vascular surgery (MaVS) [abstract].
        Can J Anesth. 2004; 71: A7
        • Urban MK
        • Markowitz SM
        • Gordon MA
        • et al.
        Postoperative prophylactic administration of β-adrenergic blockers in patients at risk for myocardial ischemia.
        Anesth Analg. 2000; 90: 1257-1261
        • Wallace AW
        • Galindez D
        • Salahieh A
        • et al.
        Effect of clonidine on cardiovascular morbidity and mortality after noncardiac surgery.
        Anesthesiology. 2004; 101: 284-293
        • Stevens RD
        • Burri H
        • Tramèr MR
        Pharmacologic myocardial protection in patients undergoing noncardiac surgery: a quantitative systematic review.
        Anesth Analg. 2003; 97: 623-633
        • Poldermans D
        • Bax JJ
        • Kertai MD
        • et al.
        Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery.
        Circulation. 2003; 107: 1848-1851
        • Durazzo AE
        • Machado FS
        • Ikeoka DT
        • et al.
        Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial.
        J Vasc Surg. 2004; 39: 967-975